Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bio-Rad Laboratories

Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the Life Sciences and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, and test kits. The company was founded by David S. Schwartz and Alice N. Schwartz in 1952 and is headquartered in Hercules, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bio-Rad Laboratories reports robust earnings, eyes growth through new products

Bio-Rad Laboratories showcased strong financial performance, operational improvements, and strategic initiatives during the Q4 2022 earnings call. Despite challenges like supply chain disruptions and margin impacts, the company remains optimistic about its growth prospects and commitment to long-term targets.

Bio-Rad reports resilient Q1 performance amidst challenges and opportunities

Bio-Rad Laboratories navigated challenges in Q1 2023 to achieve core sales growth and solid non-GAAP net income, with a revised 2023 outlook projecting 4.5% revenue growth.
The impact of Russian sanctions and margin improvement plans were key discussion points, alongside the company's focus on expense management and operational transformation.
With a strategic approach to growth, strong performance in key business segments, and a focus on operational efficiency, Bio-Rad aims to capitalize on opportunities for expansion and resilience.

Bio-Rad reports Q2 earnings decline, eyes ddPCR growth opportunities

Bio-Rad Laboratories faced challenges in BioPharma but showed strengths in Clinical Diagnostics and Life Science segments.
Despite a decline in net sales, the company reported strong demand for ddPCR and authorized a new share repurchase program.
Anticipated challenges in BioPharma and China may impact revenue growth, but opportunities exist in expanding ddPCR sales and cost-saving measures.
The company maintains a strong cash position, views its valuation favorably, and plans to participate in upcoming healthcare conferences.

Bio-Rad Labs faces Q3 challenges, eyes ddPCR market growth

Bio-Rad Laboratories faced challenges in Q3 2023 due to biopharma segment issues and economic constraints in China, impacting revenue and forecasting.
Despite weaknesses, the company saw growth in Clinical Diagnostics revenue and remains focused on operational transformation and strategy execution.
Analysts raised concerns about market dynamics and share losses, while Bio-Rad plans to address challenges and capitalize on opportunities in the ddPCR market.
The company anticipates a strong Q4 to offset Q3 challenges and is prepared for potential macroeconomic impacts on biotechnology spending.

Bio-Rad Labs reports Q4 revenue decline, eyes growth opportunities

Bio-Rad Laboratories navigated challenges in Q4 2023, with revenue declines but operational resilience in key segments.
The company faces headwinds in the China market but sees opportunities in new product launches and market recovery.
Financial stability is evident with strong cash reserves, while strategic adjustments are needed to drive future growth.
Guidance for 2024 hints at a potential turnaround, with a focus on operational efficiency and revenue expansion.

Bio-Rad Laboratories reports mixed Q1 performance, maintains outlook optimism

Bio-Rad Laboratories' Q1 2024 earnings call highlighted a mixed performance with declines in Life Science sales but growth in Clinical Diagnostics. Despite challenges in certain segments, the company maintains its full-year outlook and is optimistic about long-term growth strategies and market trends.

Bio-Rad Laboratories reports solid Q2 performance amidst global spending constraints

Bio-Rad Laboratories had a solid quarter but revised full-year outlook due to global spending constraints.
Operational improvements and successful share repurchases demonstrate resilience and strategic focus.
Challenges in the Life Science group highlight areas for improvement and strategic decision-making.

Bio-Rad Laboratories exceeds revenue targets in Q3 2024 earnings call

Bio-Rad Laboratories reported a strong Q3 performance with revenue surpassing targets driven by product mix and cost efficiencies.
While facing challenges in certain segments, opportunities lie in the expected return to growth in 2025 and the expansion of the Droplet Digital PCR franchise.
Maintained revenue guidance for 2024 with margin improvements and a focus on corporate transformations and acquisitions for future growth.
Analyst questions during the call covered a range of topics including margins, market dynamics, and product pricing.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, and test kits. The company was founded by David S. Schwartz and Alice N. Schwartz in 1952 and is headquartered in Hercules, CA.

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, will report its financial results for the first quarter of 2023 on Thursday, May 4, 2023, following the close of the market. Management will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day. To participate, call 833-470-1428 within the U.S. or +1 929-526-1599 outside the U.S.

Bio-Rad to Report First Quarter 2023 Financial Results on Thursday, May 4, 2023

Investors are optimistic about Bio-Rad (BIO) on robust growth in Life Science and Clinical Diagnostics arms.

Here's Why Investors Should Buy Bio-Rad (BIO) Stock Now

Alaska Air Group

Delta Air Lines

GE HealthCare Technologies Inc

Halliburton

Jacobs Solutions Inc

Synopsys

Targa Resources

Vici Properties

Zoetis

Finding S&P 500 stocks that analysts agree on is rare. So when you see nearly unanimous agreement on some, that's quite a statement.

Analysts Agree Now's The Time To Buy These 10 Promising Stocks

Bruker

QIAGEN

This year the National Institutes of Health is set to request its biggest budget yet for 2024, on the heels of its previous biggest budget in 2023. As the COVID-19 pandemic fades from view, labs will switch back to other avenues of research, often funded by the NIH.

The 3 Most Promising Biotech Stocks to Buy Now

The mean of analysts' price targets for Bio-Rad (BIO) points to a 28.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Predict a 28.56% Upside in Bio-Rad (BIO): Here's What You Should Know

Investors are optimistic about Bio-Rad (BIO), owing to robust demand in Life Science and Clinical Diagnostics arms.

Here's Why You Should Retain Bio-Rad (BIO) Stock for Now

Bio-Rad (BIO) experiences double-digit currency-neutral core revenue growth in the Americas and Asia in Q4.

Bio-Rad (BIO) Global Expansion Strong, FX Woe Dents Growth

Excluding COVID-related sales, Life Science revenues at Bio-Rad (BIO) increase 28.1%, primarily driven by Droplet Digital PCR, process chromatography, Western blotting and qPCR products.

Bio-Rad (BIO) Q4 Earnings Miss Estimates, Operating Margin Up

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced that the company's management will participate in a fireside chat event during Citi's 2023 Healthcare Services, MedTech, Tools & HCIT Conference on Thursday, March 2, 2023, at 11:45 AM Eastern Time (8:45 AM Pacific Time).

Bio-Rad to Participate in Citi's 2023 Healthcare Services, MedTech, Tools & HCIT Conference

Bio-Rad Laboratories, Inc. (NYSE:BIO ) Q4 2022 Earnings Conference Call February 16, 2023 5:00 PM ET Company Participants Edward Chung - Vice President, Investor Relations Ilan Daskal - Chief Financial Officer Andrew Last - Chief Operating Officer Norman Schwartz - President and Chief Executive Officer Simon May - President, Life Science Group Conference Call Participants Patrick Donnelly - Citigroup Inc. Dan Leonard - Credit Suisse Brandon Couillard - Jefferies Group LLC Jack Meehan - Nephron Research LLC Operator Good afternoon, ladies and gentlemen. Thank you for attending today's Bio-Rad Fourth Quarter and Full Year 2022 Earnings Results Conference Call.

Bio-Rad Laboratories, Inc. (BIO) Q4 2022 Earnings Call Transcript

Bio-Rad (BIO) delivered earnings and revenue surprises of -4.06% and 2.93%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Bio-Rad Laboratories (BIO) Misses Q4 Earnings and Revenue Estimates

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced financial results for the fourth quarter and full year ended December 31, 2022. Fourth-quarter 2022 net sales were $730.3 million, a decrease of 0.3 percent compared to $732.8 million reported for the fourth quarter of 2021.

Bio-Rad Reports Fourth-Quarter and Full-Year 2022 Financial Results

SAN DIEGO and HERCULES, Calif. , Feb. 8, 2023 /PRNewswire/ -- Element Biosciences, Inc. — the developer of an innovative DNA sequencing platform disrupting genomics — and Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced a partnership to demonstrate the capabilities of the Bio-Rad SEQuoia RNA Sequencing Library Preparation portfolio on the Element AVITI™ Benchtop Sequencer.

Element Biosciences and Bio-Rad Partner to Deliver Seamless RNA Sequencing Workflow Between Element's AVITI™ System and Bio-Rad's SEQuoia™ Express and SEQuoia™ Complete Stranded RNA Library Prep Kits

HERCULES, Calif.--( BUSINESS WIRE )--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, will report its financial results for the fourth quarter and full year 2022 on Thursday, February 16, 2023, following the close of the market. Management will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day.

Bio-Rad to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, February 16, 2023

Punishment of both Bio-Rad Laboratories, Inc. and Sartorius AG continued throughout the final stages of 2022. Bio-Rad Laboratories had an equally challenging Q3, setting up Q4 and FY22 numbers as key inflection points.

Bio-Rad: How Efficient Is Its Capital Management? A Deep Look, With Technicals

HERCULES, Calif.--( BUSINESS WIRE )--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced that Norman Schwartz, President and CEO, will present a company overview at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 4:30 p.m. Pacific Time. The presentation will be followed by a Q&A session with participation from Bio-Rad's Executive Vice President and COO Andrew Last, and Executive Vice President and CFO Ilan Daskal.

Bio-Rad to Present Company Overview at J.P. Morgan 41st Annual Healthcare Conference

Bio-Rad's (BIO) underlying Life Science currency-neutral core revenue growth is primarily driven by Western loading, qPCR, process media and antibody products sales.

Bio-Rad (BIO) Core Diagnostic Sales Grow Amid Supply Challenges

American Equity Investment Life

Bain Capital Specialty Finance Inc

BrightSphere Investment Group

Century Communities

Carlyle Group

Commercial Metals

What do you call a stock that has a great earnings growth history, yet sells for modest price?

The Bunny Portfolio Has Averaged 13.6% Per Year

BeiGene

Catalent

DexCom

Edwards Lifesciences

Gilead Sciences

Intuitive Surgical

Moderna

Seagen

West Pharmaceutical Services

The healthcare sector has gained momentum following the COVID-19 pandemic. Several companies gained early regulatory approval for developing COVID-19 drugs and distributing vaccines.

These Are the Five Best and Worst Performing Healthcare Stocks in October 2022

Avis Budget Group

Carlisle Companies

DoorDash

Royal Caribbean Cruises

SVB Financial Group

Schlumberger

The S&P 500 recovered in October, gaining almost 8%, but it is still down about 18% year to date.

These Were The Five Best And Worst Performing Large-Cap Stocks in October 2022

Bio-Rad To Participate in Fireside Chat During Credit Suisse's 31st Annual Healthcare Conference

Bio-Rad's (BIO) third-quarter revenues decline mainly as a result of lower COVID-related sales compared with the year-ago period.

Bio-Rad (BIO) Q3 Earnings Surpass Estimates, Margins Down

Bio-Rad Laboratories, Inc. (NYSE:BIO ) Q3 2022 Earnings Conference Call October 27, 2022 5:00 PM ET Company Participants Edward Chung - VP, IR Ilan Daskal - EVP & CFO Andrew Last - EVP & COO Norman Schwartz - Chairman, CEO & President Dara Wright - EVP & President, Clinical Diagnostics Group Simon May - EVP & President, the Life Science Group Conference Call Participants Patrick Donnelly - Citigroup Brandon Couillard - Jefferies Daniel Leonard - Crédit Suisse Jack Meehan - Nephron Research Operator Good evening, and thank you for attending today's Bio-Rad Laboratories 2022 Earnings Results Conference Call. My name is Daniel, and I will be your moderator for today's call.

Bio-Rad Laboratories, Inc. (BIO) Q3 2022 Earnings Call Transcript

Bio-Rad (BIO) delivered earnings and revenue surprises of 0.39% and 1.34%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

News for Bio-Rad Laboratories Stock (BIO)